Search

Displaying results 4351 - 4360 of 10000 in total
  1. Drug

    CNS-5161

    go.drugbank.com/drugs/DB05824
    Experimental

    CNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.

  2. Drug

    GnRH pharmaccine

    go.drugbank.com/drugs/DB05815
    Experimental

    The pharmaccine is administered intramuscularly to the patient by injection and induces an immune response or production of antibodies in the patient, which neutralize GnRH thus removing it from circulation … The GnRH pharmaccine consists of synthetic peptides (constructed to "look like" GnRH), which are bound chemically to a carrier and suspended in a proprietary "delivery vehicle".

  3. Drug

    Ravagalimab

    go.drugbank.com/drugs/DB16676
    Investigational

    Ravagalimab is under investigation in clinical trial NCT03695185 (A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe It Is in Participants With Moderate to Severe Ulcerative Colitis

  4. Drug

    Decamethonium

    go.drugbank.com/drugs/DB01245
    Approved

    Decamethonium is used in anesthesia to cause paralysis. It is a short acting depolarizing muscle relaxant. … It is similar to acetylcholine and acts as a partial agonist of the nicotinic acetylcholine receptor.

    Synonyms: N,N,N,N',N',N'-hexamethyl-1,10-decanediaminium, Decamethonium ion
  5. Drug

    MKC1106-PP

    go.drugbank.com/drugs/DB06030
    Experimental

    MKC1106-PP was under investigation in clinical trial NCT00423254 (Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.). … MKC1106-PP is a 3-component investigational vaccine made up of a DNA plasmid (pPRA-PSM) and 2 peptides E-PRA and E-PSM.

  6. Drug

    Crotalus scutulatus antivenin

    go.drugbank.com/drugs/DB13891
    Approved

    CroFab is more specifically tailored for crotalids of North America and is less allergenic than whole immunoglobulin antivenoms [L2861]. … It is intravenously administered to limit systemic toxicity [FDA label], [L2857], [L2858].

  7. Drug

    Dehydroascorbic acid

    go.drugbank.com/drugs/DB08830
    Experimental

    Dehydroascorbic acid as well as ascorbic acid are both termed Vitamin C, but the latter is the main form found in humans. … Currently dehydroascorbic acid is an experimental drug with no known approved indications.

  8. Drug

    Levopropoxyphene

    go.drugbank.com/drugs/DB06793
    ApprovedWithdrawn

    Levopropoxyphene is a stereoisomer of propoxyphene in the form of 2S, 3R enantiomer. It was sold as an antitussive, but it was removed from the market in the 70s. … [T133] Levopropoxyphene was developed by Lilly and FDA approved on March 21st, 1962. This drug presented different dosages and it was administered as a capsule or suspension.

  9. Drug

    LCP-AtorFen

    go.drugbank.com/drugs/DB05769
    Investigational

    LCP-AtorFen is designed to be a once daily tablet offering a powerful and safe treatment of high cholesterol levels, addressing three primary cardiovascular risk factors: low density lipoprotein cholesterol … LCP-AtorFen is a fixed-dose combination therapy for the treatment of high cholesterol levels combining atorvastatin (the active ingredient of Lipitor®) and the lowest dose of fenofibrate without food effect

  10. Drug

    Veru-111

    go.drugbank.com/drugs/DB16462
    Investigational

    VERU-111, an investigational drug intended for various therapeutic uses, was under investigation in clinical trials NCT04842747, NCT03752099, NCT04388826, NCT04844749, NCT05008510, and NCT05079360. … These trials aimed to evaluate its efficacy, safety, and tolerability in conditions such as SARS-CoV-2 infection, metastatic castration-resistant prostate cancer (mCRPC), respiratory distress syndrome

    Categories: Experimental Unapproved Treatments for COVID-19